Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murray Epstein

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Annals of Internal Medicine|June 3, 2009
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertensionJames R Sowers, Adam Whaley-Connell, Murray Epstein
Journal of Clinical Pharmacology|July 3, 2002
Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitusRichard A Preston, Neyton M Baltodano, Alberto B Alonso, et al.
Journal of the Cardiometabolic Syndrome|September 6, 2007
Atorvastatin does not induce glomerular or tubular dysfunction even at high dosesMurray Epstein, Elizabeth Leary, Rachel Laskey, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 3, 2022
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment ParadigmsMurray Epstein, Csaba P Kovesdy, Catherine M Clase, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 2, 2021
Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the RisksMurray Epstein, Roberto Pecoits-Filho, Catherine M Clase, et al.
The American Journal of Managed Care|December 1, 2015
Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitorsMurray Epstein, Nancy L Reaven, Susan E Funk, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 25, 2023
Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical TrialsDavid A Bushinsky, Jeffrey J Budden, Philip A Kalra, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetesMurray Epstein, Gordon H Williams, Myron Weinberger, et al.
Journal of Hypertension|January 28, 2017
Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diureticsMatthew R Weir, Martha R Mayo, Dahlia Garza, et al.
The American Journal of Managed Care|September 27, 2016
Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitorsMurray Epstein, Paula J Alvarez, Nancy L Reaven, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Annals of Internal Medicine|June 3, 2009
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertensionJames R Sowers, Adam Whaley-Connell, Murray Epstein
Journal of Clinical Pharmacology|July 3, 2002
Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitusRichard A Preston, Neyton M Baltodano, Alberto B Alonso, et al.
Journal of the Cardiometabolic Syndrome|September 6, 2007
Atorvastatin does not induce glomerular or tubular dysfunction even at high dosesMurray Epstein, Elizabeth Leary, Rachel Laskey, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 3, 2022
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment ParadigmsMurray Epstein, Csaba P Kovesdy, Catherine M Clase, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 2, 2021
Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the RisksMurray Epstein, Roberto Pecoits-Filho, Catherine M Clase, et al.
The American Journal of Managed Care|December 1, 2015
Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitorsMurray Epstein, Nancy L Reaven, Susan E Funk, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 25, 2023
Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical TrialsDavid A Bushinsky, Jeffrey J Budden, Philip A Kalra, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetesMurray Epstein, Gordon H Williams, Myron Weinberger, et al.
Journal of Hypertension|January 28, 2017
Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diureticsMatthew R Weir, Martha R Mayo, Dahlia Garza, et al.
The American Journal of Managed Care|September 27, 2016
Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitorsMurray Epstein, Paula J Alvarez, Nancy L Reaven, et al.
Pageof 8